SCHEMBL4300876

SCHEMBL4300876

Cn1ccnc1-c1cc2nccc(Oc3ccc(N(C(=O)Cc4ccc(F)cc4)C(N)=S)cc3F)c2s1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 20/20 0.59
KDR P35968 19/20 0.59
MST1R Q04912 2/20 0.46
FLT1 P17948 1/20 0.45
FLT4 P35916 1/20 0.45
AURKA O14965 1/20 0.44
FPR1 P21462 1/20 0.44
FPR3 P25089 1/20 0.44
GPR183 P32249 1/20 0.44
SMO Q99835 1/20 0.44
GPR35 Q9HC97 1/20 0.44
PLK4 O00444 1/20 0.43
MAP4K4 O95819 1/20 0.43
ABL1 P00519 1/20 0.43
LCK P06239 1/20 0.43
FYN P06241 1/20 0.43
LYN P07948 1/20 0.43
HCK P08631 1/20 0.43
PDGFRB P09619 1/20 0.43
BCR P11274 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4297500 0.94 MET (0.66) METKDRMST1RFLT1FLT4
SCHEMBL4300690 0.93 MET (0.52) METKDRMST1RFLT1FLT4
SCHEMBL4298150 0.91 MET (0.51) METKDRMST1RFLT1FLT4
SCHEMBL4300913 0.88 MET (0.64) METKDRMST1RFLT1FLT4
SCHEMBL4296630 0.84 MET (0.56) METKDRMST1RFLT1FLT4
SCHEMBL4294359 0.82 MET (0.52) METKDRMST1RFLT1FLT4
SCHEMBL896364 0.80 MET (0.55) METKDRMST1RFLT1FLT4
SCHEMBL3621597 0.80 MET (0.89) METKDRMST1RFLT1FLT4
SCHEMBL4709277 0.80 MET (0.65) METKDRMST1RFLT1FLT4
SCHEMBL3574199 0.79 MET (0.75) METKDRFLT1FLT4AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270391-A1 THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY KIRIN PHARMA KABUSHIKI KAISHA (JP) 2009-10-29 US claimed
US-20090270391-A1 THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY KIRIN PHARMA KABUSHIKI KAISHA (JP) 2009-10-29 US disclosed
EP-1870414-A1 THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING C-MET AUTOPHOSPHORYLATION INHIBITING POTENCY Kirin Pharma Kabushiki Kaisha (JP) 2007-12-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270391-A1 THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY MET, ABL1, RET MET 1/4885KDR 39/4885MST1R 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.